- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Knowing Your Hereditary Risk
In this special edition of the CURE Talks Cancer podcast, we kick off National Hereditary Breast and Ovarian Cancer Week and Previvor Day.
In 2010, history was made when a Congressional resolution was passed to declare the first-ever National Hereditary Breast and Ovarian Cancer Week and National Previvor Day to raise awareness about hereditary cancer.
Millions of people carry an inherited mutation or have a family history of cancer but many don't know about their risk. National Hereditary Breast and Ovarian Cancer Week and Previvor Day aim to change that.
In this special edition of the CURE Talks Cancer, we spoke with president and CEO of My Gene Counsel, Ellen Matloff, and founder of Proactive Genes, Shannon Pulaski, to help kick off National Hereditary Breast and Ovarian Cancer Week and Previvor Day. In this episode you’ll hear about their resources and how each can help others learn more about their hereditary risk.
Dato-DXd Extends PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Dato-DXd (datopotamab deruxtecan) as a form of treatment compared to chemotherapy resulted in improved progression-free survival for patients with previously treated hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Read More
Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
November 30th 2023Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Listen
Keytruda Plus Chemo Improves Complete Response Rate in Breast Cancer
December 7th 2023The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer.
Read More
